Announcements Trials
Browse Landscape

Phase

Phase 2 409Phase 1 176Phase 1/2 157Phase 3 137Phase 4 12Phase NA 10Phase EARLY_PHASE1 8Phase 2/3 7

Status

Completed 3Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 5Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2/3 × Lenalidomide × Clear all
NCT07095452 2026-05-27

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

AbbVie

Phase 2/3 Recruiting
660 enrolled
Plasma cell

Multiple Myeloma

NCT07428369 2026-02-23

LINKER-MM8

Regeneron Pharmaceuticals

Phase 2/3 Not yet recruiting
1,570 enrolled
Plasma cell

Multiple Myeloma

NCT03759093 2023-09-06

CURATE.AI Optimized Modulation for Multiple Myeloma

National University Hospital, Singapore

Phase 2/3 Unknown
20 enrolled
Plasma cell

Multiple Myeloma

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02145598 2019-01-16

GERMAIN

University of Jena

Phase 2/3 Terminated
85 enrolled
Plasma cell

Multiple Myeloma

NCT02419118 2017-11-07

DARA

Vejle Hospital

Phase 2/3 Completed
4 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Celgene

Phase 2/3 Completed
274 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡